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The enzymes of the shikimate pathway are attractive targets for new-generation
antimicrobial agents. The first step of this pathway is catalysed by 3-deoxy-
d-arabino-heptulosonate-7-phosphate (DAH7P) synthase and involves the
condensation of phosphoenolpyruvate (PEP) and erythrose 4-phosphate
(E4P) to form DAH7P. DAH7P synthases have been classified into two
apparently evolutionarily unrelated types and whereas structural data have been
obtained for the type I DAH7P synthases, no structural information is available
for their type II counterparts. The type II DAH7P synthase fromMycobacterium
tuberculosis was co-expressed as native and selenomethionine-substituted
protein with the Escherichia coli chaperonins GroEL and GroES in E. coli,
purified and crystallized. Native crystals of M. tuberculosis DAH7P synthase
belong to space group P3121 or P3221 and diffract to 2.5 A˚, with unit-cell
parameters a = b = 203.61, c = 66.39 A˚. There are either two or three molecules
in the asymmetric unit. Multiwavelength anomalous diffraction (MAD) phasing
using selenomethionine-substituted protein is currently under way.
1. Introduction
3-Deoxy-d-arabino-heptulosonate-7-phosphate (DAH7P) synthase
(EC 2.5.1.54) catalyses a condensation reaction between phospho-
enolpyruvate (PEP) and erythrose 4-phosphate (E4P) to form
DAH7P (Fig. 1). This reaction is the first step of the shikimate
pathway, a series of seven enzyme-catalysed reactions that are
responsible for the biosynthesis of chorismate, a precursor for
aromatic compounds including the aromatic amino acids (Bentley,
1990). The shikimate pathway is found in microorganisms and plants
but is absent in higher organisms, making the enzymes of this
pathway attractive as targets for the development of novel anti-
microbial agents. One of the most important current challenges for
drug discovery is the development of new antibiotics for Myco-
bacterium tuberculosis, which is the cause of tuberculosis (TB) and is
responsible for over two million deaths annually (Rattan et al., 1998).
Although effective anti-TB drugs exist, the long treatment times
required, the problems of latent or persistent TB (Parrish et al., 1998)
and the proliferation of multidrug-resistant strains of M. tuberculosis
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Figure 1
Biosynthesis of aromatic amino acids via the shikimate pathway.
(Stokstad, 2000) have all created an urgent need for the development
of new antimycobacterial agents. Recent gene-disruption studies
have shown that operation of the shikimate pathway is essential for
the viability of M. tuberculosis (Parish & Stoker, 2002) and enzymes
from this pathway are thus valid targets.
DAH7P synthases can be classified into two types based on
sequence similarity and molecular weight (Walker et al., 1996).
Analysis of the genome of M. tuberculosis reveals the presence of a
single gene encoding a DAH7P synthase belonging to the type II
family. Although X-ray crystal structures have been determined for
the type I enzymes from Escherichia coli (Shumilin et al., 1999, 2003),
Saccharomyces cerevisiae (Hartmann et al., 2003; Konig et al., 2004),
Thermotoga maritima (Shumilin et al., 2004) and Pyrococcus furiosus
(Schofield et al., 2005), there is limited functional and no structural
information available for the type II enzymes.
Type II DAH7P synthases comprise a separate homologous group
distinct from the type I enzymes (Gosset et al., 2001; Jensen et al.,
2002). Structural information for this group is required to determine
any evolutionary relationship between the two DAH7P synthase
families. Type II enzymes were first identified in plants (Zhao &
Herrmann, 1992; Dyer et al., 1990) and subsequently a limited
number of microbial examples were characterized (Walker et al.,
1996). However, as more microbial genomes have been sequenced
the number of type II DAH7P synthases known has grown rapidly
and it appears that this type of DAH7P synthase consists of a subset
of plant enzymes clustered within a more divergent set of microbial
enzymes (Gosset et al., 2001). In some organisms, genes encoding
both type I and type II DAH7P synthases have been identified, with
several of the type II enzymes apparently being required for the
biosynthesis of specific secondary metabolites (Silakowski et al.,
2000). However, the presence of only type II DAH7P synthases in the
predicted proteomes of a number of species including Streptomyces
species, Corynebacterium diphtheriae, Campylobacter jejuni, Agro-
bacterium tumefaciens, Novosphingobium aromaticivorans, Helico-
bacter pylori and several Mycobacteria species provides evidence for
the role of type II DAH7P synthases in aromatic amino-acid
biosynthesis. The presence of type II DAH7P synthases in a number
of important pathogenic bacteria makes them prime targets for study,
as exploitation of the differences between the two types may enable
the development of narrow-spectrum antibiotics.
We report here the cloning, expression, in vivo solubilization,
purification and crystallization of the type II DAH7P synthase from
M. tuberculosis. The in vivo solubilization was achieved by co-
expression with the E. coli chaperonins GroEL and GroES in E. coli.
2. Materials and methods
2.1. Protein expression and purification
The DNA encoding the opening reading frame encoding
M. tuberculosis DAH7P synthase (Rv2178c) was amplified from
M. tuberculosis H37Rv genomic DNA using the polymerase chain
reaction (PCR) with primers designed to introduce NcoI and SacI
restriction sites at the 50 and 30 ends, respectively. The PCR product
was cloned into a pProExHTa (Novagen) expression vector, yielding
a protein containing an N-terminal tobacco etch virus (TEV)
protease-cleavable His tag upstream of the predicted translation start
site, so that cleavage with rTEV would yield a protein with the
addition of two N-terminal residues (AG). For the production of
soluble protein, the plasmid was transformed into E. coli BL21 (DE3)
cells containing the pGroESL plasmid (Goloubinoff et al., 1989).
Transformed E. coli cells were grown in Luria broth (LB) medium at
310 K with shaking until mid-logarithmic phase (OD600 ’ 0.4–0.6).
The growth temperature was then lowered to 298 K and isopropyl--
d-thiogalactopyranoside (IPTG; Applichem) was added to a final
concentration of 1 mM to induce expression. 6 h after induction, the
cells were harvested via centrifugation (6400g for 20 min) and stored
at 203 K until lysis.
The cell pellet was re-suspended in lysis buffer [20 mM bis-Tris
propane pH 7.5, 150 mM NaCl, 0.5 mM Tris(2-carboxyethyl)phos-
phine hydrochloride (TCEP), 0.005%(v/v) THESIT, 200 mM PEP,
100 mM MnSO4] and lysed by passage through a cell disrupter
(Constant Cell Disrupter Systems) at 97 MPa. The DNAwas broken
up by sonication and the cell debris was removed by centrifugation
(27 000g for 15 min). The crude lysate was filtered through a 0.8 mm
filter and then loaded onto a HiTrap NTA column (Amersham
Biosciences) that had been previously charged with Ni2+ ions. The
column was washed with five column volumes of lysis buffer before
the bound proteins were eluted with a linear gradient of 0–500 mM
imidazole in lysis buffer. The fractions exhibiting DAH7P synthase
activity were pooled, exchanged into lysis buffer by dilution and
concentration (10 kDa molecular-weight cutoff ultrafiltration device)
and then incubated for up to 15 h at 295 K with rTEV protease
(0.1 mg per litre of culture). The enzyme preparation was then
concentrated to no more than 5 mg ml1 using an ultrafiltration
device with a 10 kDa molecular-weight cutoff (Vivascience) and
further purified by size-exclusion chromatography on a Superdex
S200 column (Amersham Biosciences), which also removed the
rTEV protease.
DAH7P synthase activity was measured by monitoring the loss of
PEP at 232 nm (" = 2.8  103 M1 cm1 at 303 K) in the presence of
E4P using a Varian Cary 1 UV–visible spectrophotometer.
This procedure yielded approximately 4 mg homogeneous
M. tuberculosis DAH7P synthase from a 1 l culture. The protein
solution was concentrated to approximately 3 mg ml1 for crystal-
lization trials. For production of selenomethionine (SeMet) substi-
tuted protein, the plasmid bearing Rv2178c was transformed into
cells of the methionine auxotroph DL41(DE3) that also contained
pGroESL. The transformed cells were grown in minimal media with
SeMet as the only methionine source (Hendrickson et al., 1990). The
SeMet-substituted protein was then purified using an identical
protocol to that used for the native protein,
2.2. Crystallization
Screening for crystallization conditions was achieved using sitting-
drop vapour diffusion in 96-well Intelliplates (Hampton Research) at
291 K by mixing 100 nl protein solution (3 mg ml1 in lysis buffer)
with 100 nl reservoir solution and equilibrating against 75 ml reservoir
solution. The initial screens were set up using the Centre for Mole-
cular Biodiscovery Crystallization facility (http://cmb1.auckland.ac.nz/),
which consists of a modified Perkin–Elmer Multiprobe robot for the
transfer of precipitant solutions from pre-made stock into Intelli-
plates and a Cartesian Honeybee robot for setting up the nanolitre
crystallization experiments. Initial screens included Hampton Crystal
Screens I and II (Hampton Research), a systematic PEG–pH screen
(Kingston et al., 1994), a PEG/Ion screen (Hampton Research) and
the Footprint Screen (Stura et al., 1992).
Small crystals appeared within 2–3 h in several conditions and
larger needle crystals in 1–2 d in many different conditions. Further
manual screening in 24-well plates (1 + 1 ml drops, 500 ml reservoir
solution) was performed using these lead conditions. The precipitant
condition that gave the most reproducible crystals comprised 0.1M
Tris–HCl pH 8.5, 1.5M ammonium sulfate, 12%(v/v) glycerol
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(Crystal Screen II No. 42). Refinement of crystallization conditions
was achieved by altering the precipitant concentration and the pH.
The best diffracting crystals were grown with 0.1M Tris–HCl pH 8.0,
1.5M ammonium sulfate, 12%(v/v) glycerol. The crystals grew to
approximately 0.3  0.05  0.05 mm (Fig. 2). SeMet-substituted
protein formed crystals using the same protein concentration that
were of similar size and morphology. The best SeMet-substituted
crystals were grown using the following three conditions: 0.1M Na
HEPES pH 7.5, 0.8M sodium potassium tartrate (Crystal Screen I
No. 29), 0.1M Na HEPES pH 7.5, 1.5M lithium sulfate (Crystal
Screen I No. 16) and 0.1M sodium citrate pH 5.6, 1M ammonium
phosphate (Crystal Screen I No. 11).
2.3. Data collection
Native crystals were soaked in a cryoprotectant solution consisting
of 0.1M Tris–HCl pH 8.0, 1.5M ammonium sulfate supplemented
with 25%(v/v) glycerol and were flash-frozen under a stream of cold
nitrogen at 110 K. X-ray diffraction data were collected using a
Rigaku MicroMax007 generator with Osmic blue optics and an
R-AXIS IV++ detector. A highly redundant native data set was
collected to a maximum resolution of 2.5 A˚ and an overall Rmerge of
9.9% on intensities, using non-overlapping 0.3 oscillations collected
for 15 min per frame at a crystal-to-detector distance of 180 mm
(Table 1). Data were processed using CrystalClear v.1.3.6 (Rigaku).
3. Results and discussion
When M. tuberculosis DAH7P synthase was expressed in E. coli, no
soluble recombinant protein was observed and the supernatant
fraction showed no detectable enzymatic activity. Alteration of
growth temperature and lysis conditions had no effect on the protein
solubility. We therefore used co-expression with E. coli GroESL to
solublize DAH7P synthase, following our previous successful solu-
bilization of the type II DAH7P synthase from H. pylori (CJW and
EJP, unpublished observations). Although the majority of the protein
remained insoluble, approximately 30% of the total protein
expressed was found in the supernatant following lysis and centri-
fugation and this exhibited DAH7P synthase activity. The incor-
poration of PEP, MnSO4, TCEP and NaCl in all purification buffers
was essential in order to prevent aggregation of the protein. The
molecular weight of the recombinant protein after cleavage with
rTEV was 50 kDa and the protein preparation was essentially pure
(>95%) as estimated by SDS–PAGE. Crystallization trials were
performed using protein concentrations no greater than 5 mg ml1, as
protein precipitation was observed at higher concentrations. The
crystals were found to be trigonal, with systematic absences consis-
tent with the space group P3121 or P3221. The unit-cell parameters,
a = b = 203.61, c = 66.39 A˚, are consistent with the presence of two or
three molecules in the crystal asymmetric unit, corresponding to
values of the Matthews coefficient VM of 3.9 and 2.6 A˚
3 Da1 and
solvent contents of 68 and 53%, respectively. Size-exclusion chro-
matography indicates that M. tuberculosis DAH7P synthase behaves
as a dimer in solution (data not shown).
Molecular replacement was attempted using E. coli type I DAH7P
synthase as a model and found to be unsuccessful. We are currently
trying to solve the structure of M. tuberculosis DAH7P synthase by
multiwavelength anomalous diffraction (MAD) methods using
SeMet-substituted protein, given that the DAH7P synthase monomer
contains 13 methionines.
We thank Mark Patchett for the pGroESL plamid and Geoffrey
Jameson and Gillian Norris for assistance in obtaining the native data
set. CJW is a recipient of a Massey University Vice Chancellor’s
scholarship. This work was funded by the RSNZ Marsden Fund
(MAU008) and the Centre for Molecular Biodiscovery.
References
Bentley, R. (1990). Crit. Rev. Biochem. Mol. Biol. 25, 307–384.
Dyer, W. E., Weaver, L. M., Zhao, J., Kuhn, D. N., Weller, S. C. & Herrmann,
K. M. (1990). J. Biol. Chem. 265, 1608–1614.
Goloubinoff, P., Gatenby, A. A. & Lorimer, G. H. (1989). Nature (London),
337, 44–47.
Gosset, G., Bonner, C. A. & Jensen, R. A. (2001). J. Bacteriol. 183, 4061–4070.
Hartmann, M., Schneider, T. R., Pfeil, A., Heinrich, G., Lipscomb, W. N. &
Braus, G. H. (2003). Proc. Natl Acad. Sci. USA, 100, 862–867.
Hendrickson, W. A., Horton, J. R. & LeMaster, D. M. (1990). EMBO J. 9,
1665–1672.
Jensen, R. A., Xie, G., Calhoun, D. H. & Bonner, C. A. (2002). J. Mol. Evol. 54,
416–423.
Kingston, R. L., Baker, H. M. & Baker, E. N. (1994).Acta Cryst.D50, 429–440.
Konig, V., Pfeil, A., Braus, G. H. & Schneider, T. R. (2004). J. Mol. Biol. 337,
675–690.
Parish, T. & Stoker, N. G. (2002). Microbiology, 148, 3069–3077.
Parrish, N. M., Dick, J. D. & Bishai, W. R. (1998). Trends Microbiol. 6, 107–112.
Rattan, A., Kalia, A. & Ahmad, N. (1998). Emerging Infect. Dis. 4, 195–209.
Schofield, L. R., Anderson, B., Norris, G. E., Patchett, M. L., Jameson, G. B. &
Parker, E. J. (2005). In preparation.
Shumilin, I. A., Bauerle, R. & Kretsinger, R. H. (2003). Biochemistry, 42,
3766–3776.
crystallization communications
Acta Cryst. (2005). F61, 403–406 Webby et al.  DAH7P synthase 405
Figure 2
Crystals of M. tuberculosis DAH7P synthase.
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